Home Cart Sign in  
Chemical Structure| 20874-52-6 Chemical Structure| 20874-52-6

Structure of Saikosaponin D
CAS No.: 20874-52-6

Chemical Structure| 20874-52-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Saikosaponin D, a natural product isolated and purified from the herb of Bupleurum chinense DC., is a SERCA inhibitor by inhibiting NF-κB and STAT3 signaling to protect against acetaminophen-induced hepatotoxicity and a potent inhibitor on acute hepatic injury by CCl4 and a potent cytotoxicity agent for human hepatocellular carcinoma cells, and has the antiproliferative effect in A549 cells that may be the induction of p53 and activity of the Fas/FasL apoptotic system.

Synonyms: Saikosaponin D

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Saikosaponin D

CAS No. :20874-52-6
Formula : C42H68O13
M.W : 780.98
SMILES Code : CC1(C)CC[C@]2(CO3)[C@H](O)C[C@@]4(C)[C@]([C@]5([H])C=C[C@]43[C@]2([H])C1)(C)CC[C@@]([C@]5(C)CC6)([H])[C@@](CO)(C)[C@H]6O[C@@](O[C@H](C)[C@@H]7O)([H])[C@H](O)[C@H]7O[C@@]8([H])[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8
Synonyms :
Saikosaponin D
MDL No. :MFCD09028095
InChI Key :KYWSCMDFVARMPN-LCSVLAELSA-N
Pubchem ID :107793

Safety of Saikosaponin D

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Saikosaponin D

JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Hippocampal neural progenitor cells (NPCs) 5.13 µM (EC50) 24 hours SSd inhibited the survival and proliferation of NPCs and induced apoptosis by activating the NRAGE/NADE/NRIF apoptotic signaling pathway. Clin Transl Med. 2020 Dec;10(8):e243
HepG2 cells 7.5-15 µM 24 hours Induced autophagy and apoptosis, detected by GFP-LC3 puncta formation and Annexin V staining. Cell Death Dis. 2013 Jul 11;4(7):e720
HepG2 cells 7.5-15 µM 24 hours Induced autophagy and apoptosis, confirmed by GFP-LC3 puncta formation and Annexin V staining. Cell Death Dis. 2013 Jul 11;4(7):e720
MCF-7 cells 10 µM 4 hours Induced autophagy, detected by GFP-LC3 puncta formation and increased LC3-II protein levels. Cell Death Dis. 2013 Jul 11;4(7):e720
HeLa cells 10 µM 4 hours Induced autophagy, detected by GFP-LC3 puncta formation and increased LC3-II protein levels. Cell Death Dis. 2013 Jul 11;4(7):e720
MCF-7 cells 10 µM 4 hours Induced autophagy, confirmed by GFP-LC3 puncta formation and increased LC3-II protein expression. Cell Death Dis. 2013 Jul 11;4(7):e720
HeLa cells 10 µM 4 hours Induced autophagy, confirmed by GFP-LC3 puncta formation and increased LC3-II protein expression. Cell Death Dis. 2013 Jul 11;4(7):e720
U937 cells 1 µM 48 hours Inhibited cell proliferation, promoted apoptosis and cell-cycle arrest Theranostics. 2021 Mar 31;11(12):5831-5846
MV4-11 cells 1 µM 48 hours Inhibited cell proliferation, promoted apoptosis and cell-cycle arrest Theranostics. 2021 Mar 31;11(12):5831-5846
Kasumi-1 cells 1 µM 48 hours Inhibited cell proliferation, promoted apoptosis and cell-cycle arrest Theranostics. 2021 Mar 31;11(12):5831-5846
NB4 cells 1 µM 48 hours Inhibited cell proliferation, promoted apoptosis and cell-cycle arrest Theranostics. 2021 Mar 31;11(12):5831-5846
HeLa cells 15 µM 6 hours To assess the ability of SsD to modulate autophagy, it was found that SsD significantly inhibited the fusion of autophagosomes and lysosomes, leading to the accumulation of autophagosomes, increased lysosomal pH, and TFEB nuclear translocation. Signal Transduct Target Ther. 2019 Feb 22;4:4

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6N mice Leukemia model Intraperitoneal injection 0.1 mg/kg or 0.5 mg/kg 3 times per week for 3 weeks Significantly inhibited leukemia progression, including reduced WBC count, decreased leukemic blasts in BM, reduced splenomegaly, inhibited lung metastasis and prolonged survival Theranostics. 2021 Mar 31;11(12):5831-5846
C57BL/6J mice Cognitive dysfunction model Oral gavage 16 mg/kg Once daily for 14 consecutive days SSd inhibited hippocampal neurogenesis and caused cognitive dysfunction by disrupting pro-BDNF/p75NTR and BDNF/TrkB signaling pathways. Clin Transl Med. 2020 Dec;10(8):e243
Mice Experimental autoimmune encephalomyelitis (EAE) model Intragastric administration 40 mg/kg Once daily, starting from the day of immunization To investigate the therapeutic effect of SSD on EAE, results showed that SSD significantly alleviated EAE symptoms Nat Commun. 2021 Oct 27;12(1):6198

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.28mL

0.26mL

0.13mL

6.40mL

1.28mL

0.64mL

12.80mL

2.56mL

1.28mL

References

 

Historical Records

Categories